METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study aims to determine the efficacy, safety, and tolerability of the sequential
addition of immune-modulating therapy to standard-of-care therapy of microsatellite-stable
(MSS) metastatic colorectal cancer (mCRC).
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Akershus
Collaborators:
Haukeland University Hospital Hospital of Southern Norway Trust Oslo University Hospital Trondheim University Hospital